Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

International Journal of Hematology

Volumn 102, Issue 3, 2015, Pages 296-303

  Zhi, Yongjin ^a   Xie, Xiaobao ^a   Wang, Rong ^a   Wang, Biao ^a   Gu, Weiying ^a   Ling, Yun ^a   Dong, Weimin ^a   Zhi, Feng ^a   Liu, Yan ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Biomarker; MiR 10a 5p; Prognosis

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MICRORNA; MICRORNA 10 5P; NUCLEOPHOSMIN; UNCLASSIFIED DRUG; MIRN10 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; SPLENOMEGALY; THROMBOCYTE COUNT; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; LEUKEMIA, MYELOID, ACUTE; MORTALITY; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84941261316     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1829-6     Document Type: Article

References (41)

1. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88(4):318–27.
2. Estey E., Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–907.
3. Zhu YD, Wang L, Sun C, et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol. 2012;29(4):2323–31.
4. Osada H., MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28(1):2–12.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
6. Lujambio A., The microcosmos of cancer. Nature. 2012;482(7385):347–55.
7. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer. 2003;3(4):243–52.
8. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148.
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.
10. Debernardi S, Skoulakis S, Molloy G, et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia. 2007;21(5):912–6.
11. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
12. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58 (10):1375-1381.
13. Ovcharenko D, Stolzel F, Poitz D, et al. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol 2011;39 (10):1030–1042 (e1037).
14. Bryant A, Palma CA, Jayaswal V, et al. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer. 2012;11:8.
15. Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS ONE. 2013;8(2):e56718.
16. Cull EH, Altman JK. Contemporary treatment of APL. Curr Hematol Malig Rep 2014;9 (2):193–201.
17. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–9.
18. Fayyad-Kazan H, Bitar N, Najar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31.
19. Nonaka R, Nishimura J, Kagawa Y, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 2014;32(6):2354–8.
20. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9.
21. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32(2):326–48.
22. Tallman MS, Gilliland DG, Rowe JM, et al. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63.
23. Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46(11):1511–7.
24. Mansfield JH, Harfe BD, Nissen R, et al. MicroRNA-responsive ‘sensor’ transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet. 2004;36(10):1079–83.
25. Lund AH. miR-10 in development and cancer. Cell Death Differ. 2010;17(2):209–14.
26. Long MJ, Wu FX, Li P, et al. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012;324(2):186–96.
27. Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34 + cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830–40.
28. Jia H, Zhang Z, Zou D, et al. MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS ONE. 2014;9(1):e88057.
29. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc + AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899–902.
30. Havelange V, Ranganathan P, Geyer S, et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014;123(15):2412–5.
31. Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83–6.
32. Lutherborrow M, Bryant A, Jayaswal V, et al. Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol. 2011;86(1):2–11.
33. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115–36.
34. Li X, Xu F, Chang C, et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. 2013;98(3):414–9.
35. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–77.
36. Sun W, Ma Y, Chen P, et al. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep 2015;11(5):3854–9.
37. Rushworth SA, Murray MY, Barrera LN, et al. Understanding the role of miRNA in regulating NF-kappaB in blood cancer. Am. J Cancer Res. 2012;2(1):65–74.
38. Perez-Rivas LG, Jerez JM, Carmona R, et al. A microRNA signature associated with early recurrence in breast cancer. PLoS ONE. 2014;9(3):e91884.
39. Li Z, Zhao J, Li Q, et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones. 2010;15(6):905–12.
40. Peng C, Chen Y, Li D, et al, Role of Pten in leukemia stem cells. Oncotarget 2010;1 (2):156–160.
41. LaBelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest. 2012;122(6):2018–31.